These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2642 related articles for article (PubMed ID: 7954526)

  • 21. Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage.
    Maeurer MJ; Hurd S; Martin DM; Storkus WJ; Lotze MT
    Cancer J Sci Am; 1995; 1(2):162-70. PubMed ID: 9166469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin.
    Strohal R; Paucz L; Pehamberger H; Stingl G
    Cancer Res; 1994 Sep; 54(17):4734-9. PubMed ID: 8062272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis.
    Ferradini L; Roman-Roman S; Azocar J; Avril MF; Viel S; Triebel F; Hercend T
    Cancer Res; 1992 Sep; 52(17):4649-54. PubMed ID: 1324789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of different culture protocols on the expression of discrete T-cell receptor variable regions in human tumour infiltrating lymphocytes.
    Filgueira L; Zuber M; Merlo A; Harder F; Heberer M; Spagnoli GC
    Eur J Cancer; 1993; 29A(12):1754-60. PubMed ID: 8398305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
    Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
    Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
    Kan-Mitchell J; Huang XQ; Steinman L; Oksenberg JR; Harel W; Parker JW; Goedegebuure PS; Darrow TL; Mitchell MS
    Cancer Immunol Immunother; 1993 Jul; 37(1):15-25. PubMed ID: 8513449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
    Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
    J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
    Clay TM; Custer MC; Spiess PJ; Nishimura MI
    Pathol Oncol Res; 1999; 5(1):3-15. PubMed ID: 10079371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited T cell antigen receptor repertoire in tumor-infiltrating lymphocyte and inhibition of experimental lung metastasis of murine melanoma by anti-TCR antibody.
    Wang R; Taniguchi M
    J Immunol; 1995 Feb; 154(4):1797-803. PubMed ID: 7836764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.
    Ramirez-Montagut T; Andrews DM; Ihara A; Pervaiz S; Pandolfi F; Van Den Elsen PJ; Waitkus R; Boyle LA; Hishii M; Kurnick JT
    Clin Exp Immunol; 2000 Jan; 119(1):11-8. PubMed ID: 10606959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
    Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
    J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.
    Weidmann E; Whiteside TL; Giorda R; Herberman RB; Trucco M
    Cancer Res; 1992 Nov; 52(21):5913-20. PubMed ID: 1382847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
    Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
    J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell receptor V beta gene expression differs in tumor-infiltrating lymphocytes within primary and metastatic melanoma.
    Nitta T; Bell R; Okumura K; Sato K; Steinman L
    Cancer Res; 1991 Oct; 51(20):5565-9. PubMed ID: 1655255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of T-cell receptor V beta repertoire in ovarian tumour-reacting CD3+ CD8+ CD4- CTL lines.
    Fisk B; Flytzanis CN; Pollack MS; Wharton JT; Ioannides CG
    Scand J Immunol; 1994 Dec; 40(6):591-600. PubMed ID: 7848491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1.
    Lake DF; Salgaller ML; van der Bruggen P; Bernstein RM; Marchalonis JJ
    Int Immunol; 1999 May; 11(5):745-51. PubMed ID: 10330280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expansion of major histocompatibility complex-restricted antimelanoma cytotoxic T-cell lymphocyte clones with identical T-cell receptor from tumor-infiltrating lymphocytes.
    Sensi M; Castelli C; Salvi S; Mazzocchi A; Mortarini R; Nicolini G; Anichini A; Parmiani G
    J Immunother (1991); 1992 Oct; 12(3):207-11. PubMed ID: 1332745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of restricted T-cell receptor beta-chain variable region (V beta) usage of reactive T-lymphocytes in Hodgkin's disease.
    Meggetto F; al Saati T; Rubin B; Delsol G
    Br J Haematol; 1994 Mar; 86(3):524-32. PubMed ID: 8043434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 133.